Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

She was prescribed compound semaglutide, a cheaper, custom-made version of the active drug in Ozempic and Wegovy ... So she cut back on her dosage after surgery and eventually forgot to take ...

When Rice reached her goal weight, she tried phasing out semaglutide (marketed as Wegovy for weight loss and ... restarted on a low dose to minimize costs, deciding when to start and stop without ...

Ozempic and Wegovy have been added to Medicare's list of drugs whose prices will be negotiated between drug makers and the government. There's a lot of uncertainty on which direction the Trump ...